Main focus for RDF is they need to grow their revenue line....

First 4 Last

Share
Profile

Follow
LithiumHydride

133 Posts.

3

27/02/19

15:41

Post #: 37589073
Share

Originally posted by SimonGr: ↑

I was hoping someone would have started some discussion on this as I'm only just back from hols. For those interested ...

Very much inline with what I expected when I looked at their 2Q sales activity (see post https://hotcopper.com.au/posts/37092350/single ). They didn't quite get to $30M revenue in 2Q and didn't quite get to breakeven in the half (-$0.5M excluding financing costs of ~$0.5M). With 1H confirmed, IMO I now think it's highly probably that the 2H will show RDF return to profitability and now a better than even bet that RDF will be profitable over the full FY19.

With recent significant rise in SP, I'm now well above my target weight, however I think RDF has a long way to run up as it heads back into profitability (ave analyst SP target was 80c before results came out) and if they pull a large contract win off, it could shoot up significantly. Therefore, I'm a very happy holder (but would be buying if I didn't hold so many already).

Others thoughts?

Expand

Main focus for RDF is they need to grow their revenue line. Recurring annuity revenue preferably.
The cost out that's played for the last few years, has I think, played out.
But it's left the company with a better financial standing compared to several years ago.

Would buy more except I'm at my max weighting too!

RDF Price at posting: 61.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

First 4 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Main focus for RDF is they need to grow their revenue line....

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Monash IVF shares cater 25% – Disaster or deep-value play?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Featured News